Archivio delibere
Deliberazione n.132 del 26/01/2017
Autorizzazione all’addendum 1 al contratto per lo studio: “A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC412) (IND # 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)”. Codice Protocollo CPKC412A2301. Dr. Claudio Romani, Sponsor: Novartis Farma S.p.A. – U.O.C. Ematologia e Centro Trapianti Midollo Osseo – P.O. Businco
Autorizzazione all’addendum 1 al contratto per lo studio: “A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy + midostaurin (PKC412) (IND # 101261) or placebo in newly diagnosed patients < 60 years of age with FLT3 mutated acute myeloid leukemia (AML)”. Codice Protocollo CPKC412A2301. Dr. Claudio Romani, Sponsor: Novartis Farma S.p.A. – U.O.C. Ematologia e Centro Trapianti Midollo Osseo – P.O. Businco
Data seduta:26/01/2017
In pubblicazione dal: 27/01/2017-al: 11/02/2017
In pubblicazione dal: 27/01/2017-al: 11/02/2017